Rallybio FCF par action

Que fait Rallybio ? Rallybio Corp. generates revenue by identifying, researching, and developing clinical biotechnology products and therapies for severe and rare diseases. The firm focuses on accelerating the development of life-transforming therapies, with a specific program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare hematological disease affecting fetuses and newborns. The company's pipeline includes several candidates such as RLYB212, a subcutaneously administered human monoclonal anti-HPA-1a antibody candidate for preventing HPA-1a maternal alloimmunization and FNAIT occurrence. Additionally, the advanced product candidate RLYB116 serves as an inhibitor of complement component 5 (C5) to treat complement dysregulation conditions including paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG). The pipeline also features RLYB114, a pegylated C5-targeted Affibody molecule, and the ENPP1 Program, alongside RLYB331, targeting patients with these specific medical needs. Rallybio est l'une des entreprises les plus populaires sur Eulerpool.